Expanding use of Bexxar for NHL

The new year may dawn with the US FDA allowing expanded use of the NHL drug Bexxar. Currently Bexxar is used for the treatment of patients with CD20-positive, follicular NHL, with and without transformation, whose disease is refractory to the antibody treatment Rituximab and has relapsed following chemotherapy. The expansion would allow for treating the same forms of NHL and after standard chemo relapse but would not require prior treatment with Rituxan. Good news given the cost of treatments for cancer, not having to have expensive Rituxan treatments would be good news indeed.